Obsessive Compulsive Disorder Drugs Market: Analysis Report, Share, Trends and Overview 2021-2027

The global obsessive compulsive disorder drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are propelling market growth include increasing R&D investment and a rise in clinical trials by market players, which are expected to fuel the market growth during the forecast period. Obsessive-compulsive disorder (OCD) refers to an anxiety disorder that is characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment, and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market.

A full report of Obsessive Compulsive Disorder Drugs Market is available at: https://www.omrglobal.com/industry-reports/obsessive-compulsive-disorder-drugs-market

The global obsessive compulsive disorder drugs market analysis includes some of the key market players such as Abbott Laboratories, Eli Lilly, and Company, Viatria Inc., H. Lundbeck A/S, Pfizer Inc., among others. In order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in August 2021, Alembic Pharmaceuticals declared that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Anafranil Capsules of SpecGX LLC. Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD). Alembic has a cumulative total of 149 ANDA approvals from USFDA.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/obsessive-compulsive-disorder-drugs-market

Recent Development:

• In August 2020, Sun Pharmaceutical Industries Limited announced that it had launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease. The company is launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This has supported India’s pandemic response.
• In April 2021, H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced the decision to continue recruiting patients in phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The continuation of the study enables Lundbeck and Otsuka to explore further the efficacy of brexpiprazole to address the high medical need in patients suffering from agitation in Alzheimer’s type dementia. The completion of the trial successfully will result in a new product launch, thus impacting the sales and revenue of the company.
• In June 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd. announced the U.S. launch of its generic version once-daily SOOLANTRA (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea. With the launch of products, Teva has become a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally
• Competitive Landscape: Abbott Laboratories, Eli Lilly, and Company, Viatria Inc., H. Lundbeck A/S, Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Obsessive Compulsive Disorder Drugs Market Report Segmentation

By Product

• SSRI
• TCA
• Others

Obsessive Compulsive Disorder Drugs Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Abbott Laboratories
• Eli Lilly, and Company
• Viatria Inc.
• H. Lundbeck A/S
• Pfizer Inc.

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.